Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review

Author:

Mink Sylvia12,Reimann Patrick23ORCID,Fraunberger Peter12

Affiliation:

1. Central Medical Laboratories , Feldkirch , Austria

2. Private University in the Principality of Liechtenstein , Triesen , Principality of Liechtenstein

3. Department of Internal Medicine , Academic Teaching Hospital Feldkirch , Feldkirch , Austria

Abstract

Abstract Objectives Globally, over 772 million cases of COVID-19 have been reported. New variants of interest with corresponding spikes in case numbers continue to be identified. Vulnerable patients, including older adults or patients with severe comorbidities, continue to be at risk. A large body of evidence has been accumulated regarding anti-SARS-CoV-2-antibodies and COVID-19 but the usefulness of antibody measurements remains unclear. This systematic review aims to assess the prognostic value of anti-SARS-CoV-2-antibodies and their usefulness for guiding booster vaccinations. Methods Studies in English and published between January 2020 and October 2023 were included. Studies that relied on multiparameter-models or comprised fewer than 100 participants were excluded. PubMed and via the WHO COVID-19 research database, Embase and Medline databases were searched. Study selection and quality assessment was conducted independently by two researchers. Results After screening 1,160 studies, 33 studies comprising >30 million individuals were included. Anti-SARS-CoV-2-antibodies were strongly associated with reduced risk of SARS-CoV-2-infection and better outcomes, including mortality. Risk of infection and COVID-19 severity decreased with increasing antibody levels. Conclusions Anti-SARS-CoV-2-antibodies are useful for early identification of high-risk patients and timely adjustment of therapy. Protective thresholds may be applied to advise booster vaccinations but verification in separate cohorts is required.

Publisher

Walter de Gruyter GmbH

Reference74 articles.

1. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard: situation by region, country, territory & area; 2023. https://covid19.who.int/table [Accessed 11 Dec 2023].

2. European Centre for Disease Prevention and Control. Data on testing for COVID-19 by week and country; 2023. https://www.ecdc.europa.eu/en/publications-data/covid-19-testing [Accessed 11 Dec 2023].

3. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/ [Accessed 11 Dec 2023].

4. Dyer, O. Covid-19: infections climb globally as EG.5 variant gains ground. BMJ 2023;382:1900. https://doi.org/10.1136/bmj.p1900.

5. World Health Organization (WHO). Tracking SARS-COV-2-variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants [Accessed 18 Jul 2023].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3